Quick answer: does semaglutide work for obesity?
- Across large trials (STEP program), weekly semaglutide 2.4 mg led to average weight loss of roughly 10-15% over ~68 weeks when combined with lifestyle support.
- Many participants achieved clinically meaningful milestones: for example, in STEP 1, 86% lost ≥5%, ~69% lost ≥10%, and ~50% lost ≥15% of body weight versus lifestyle alone.
- Benefits extended to blood pressure, waist circumference and glycaemic markers; a large outcomes trial (SELECT) reported fewer major cardiovascular events in adults with established CVD and overweight/obesity.
- Stopping therapy often leads to partial weight regain; ongoing care and lifestyle support remain important.
- Gastrointestinal side effects are common during titration; serious risks are uncommon but require screening and monitoring.
How semaglutide helps in obesity
Semaglutide mimics human GLP-1, a hormone that helps regulate appetite and post-meal responses. It:
- reduces hunger and food cravings
- enhances satiety signals after eating
- slows gastric emptying, supporting smaller portion sizes
- improves glucose control in people with insulin resistance or type 2 diabetes
For weight management, semaglutide is typically a once-weekly subcutaneous injection. In Australia, Wegovy (semaglutide 2.4 mg) is approved for chronic weight management. Ozempic (semaglutide) is approved for type 2 diabetes and has been used off-label for weight loss. Oral semaglutide (Rybelsus) is approved for type 2 diabetes and is not currently approved for weight loss in Australia.
Who may be eligible in Australia
Doctors generally consider semaglutide for adults with:
- BMI ≥30 kg/m² (obesity), or
- BMI ≥27 kg/m² with weight-related conditions (for example, hypertension, dyslipidaemia, obstructive sleep apnoea, insulin resistance or type 2 diabetes).
Not everyone is suitable. Doctors assess medical history, medications and risk factors. Semaglutide is typically avoided in people with:
- a personal/family history of medullary thyroid carcinoma or MEN2
- current or past pancreatitis (risk-benefit is assessed case-by-case)
- pregnancy, planning pregnancy within the next 2 months, or breastfeeding
- significant gallbladder disease without evaluation
Access, pricing and supply may vary. Wegovy is not generally PBS-subsidised for weight loss at the time of writing; Ozempic may be PBS-subsidised for eligible diabetes care. Your prescriber can advise on current stock, costs and alternatives.
What the evidence shows (STEP and SELECT)
- STEP 1 (adults with obesity or overweight without diabetes): mean weight change ~−14.9% with semaglutide 2.4 mg vs ~−2.4% with lifestyle alone at 68 weeks; higher odds of ≥5%, ≥10% and ≥15% loss.
- STEP 3 (with intensive behavioural therapy): average loss approached ~16% with semaglutide vs ~5-6% with placebo plus therapy.
- STEP 4 (maintenance/withdrawal): participants who continued semaglutide maintained and furthered weight loss; those switched to placebo regained weight, highlighting the chronic-care nature of obesity.
- STEP 8 (head-to-head): semaglutide produced greater weight loss than liraglutide (daily) in obesity management.
- SELECT (cardiovascular outcomes in adults with established CVD and overweight/obesity, mostly without diabetes): semaglutide reduced major adverse cardiovascular events compared with placebo over multi-year follow-up.
Outcomes are averages; individual results vary by adherence, dose tolerance, nutrition, physical activity, sleep and concurrent conditions.
Side effects and safety considerations
Common and usually temporary (often during dose escalation):
- nausea, vomiting, diarrhoea or constipation
- abdominal discomfort, bloating, reflux
- headache, fatigue, dizziness
- injection-site reactions
Less common but important:
- gallbladder issues (e.g., gallstones)
- pancreatitis symptoms (severe, persistent abdominal pain)
- worsening diabetic retinopathy in people with rapid HbA1c improvements
- kidney injury, usually secondary to dehydration from severe GI symptoms
- thyroid C-cell tumours occurred in rodents; relevance to humans is uncertain, but screening is standard
Drug interactions are limited, but hypoglycaemia risk increases if combined with insulin or sulfonylureas; doses may need adjustment under medical supervision. Because gastric emptying is delayed, monitoring of other oral medicines can be prudent.
Seek urgent care for severe or worsening abdominal pain, signs of dehydration, vision changes, or suspected allergic reactions.
Dosing overview and titration (informational)
Doctors typically start low and increase slowly to improve tolerability. A common Wegovy titration in Australia progresses weekly through 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg, adjusting pace to side-effects and goals. People who cannot tolerate the full 2.4 mg dose may remain at a lower maintenance dose under medical advice.
Do not change doses, double up after missed doses, or switch brands without medical guidance. If you miss a dose or have persistent side-effects, contact your prescriber for instructions tailored to your situation.
Practical tips that often improve outcomes
- Protein first: aim for sufficient daily protein to support lean mass during weight loss.
- Hydration and fibre: help manage constipation and support satiety.
- Small, slower meals: reduce GI symptoms during early titration.
- Resistance training: helps preserve muscle; combine with regular movement.
- Limit alcohol: reduces pancreatitis and reflux risks and supports sleep quality.
- Plan for maintenance: weight regain is common after stopping; discuss long-term strategies early.
Alternatives and comparisons
If semaglutide is not suitable or unavailable, doctors may consider other GLP-1 or dual-agonist options, or non-GLP-1 therapies. Compare evidence, side-effects and costs before deciding.
Frequently asked questions about semaglutide for obesity
How much weight do people usually lose?
Trial averages range around 10-15% over ~68 weeks with lifestyle support. Individual responses vary; some lose more, some less.
How long until I notice appetite changes?
Many people report reduced hunger within 1-2 weeks at low doses, with larger effects as the dose increases over several weeks.
Will weight return if I stop?
Weight regain is common after stopping. Long-term plans (nutrition, activity, sleep and, if needed, maintenance therapy) help preserve results.
Is semaglutide safe long term?
Studies extend to multiple years with ongoing monitoring. Side-effects are often GI and most prominent during titration. Suitability and monitoring plans are individualised.
Can I use it if I don't have diabetes?
Yes-Wegovy is approved for chronic weight management in adults with obesity (or overweight with comorbidities). A doctor will confirm eligibility.
Is it safe in pregnancy or when trying to conceive?
No. It's not recommended in pregnancy or breastfeeding, and is usually stopped at least 2 months before planned conception.
What if I can't tolerate higher doses?
Doctors can slow titration, pause escalation, or use a lower maintenance dose. Managing side-effects is part of routine care.
How do I access semaglutide in Australia?
Through a registered prescriber. Wegovy is approved for weight management; availability and private pricing vary. Your doctor can advise current options.
Related reading on semaglutide
Get matched with a provider
Tell us what you need. We'll match you with a provider who can help (a clinic, compounding pharmacy or supplier) and email you their introduction. Reply to it and they'll be in touch. Free, no obligation.
Prefer to read more first? See the GLP-1 Australia Guide
Final takeaway
Semaglutide is one of the most evidence-supported medical options for chronic weight management, with average losses around 10-15% alongside lifestyle changes and meaningful metabolic improvements for many. Suitability, dose and monitoring should always be individualised with a qualified prescriber.